Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

SRR8526728

— · cohortSQ1

8cf0c588-926a-50ab-bcab-f4057b86ea16

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortSQ1
subtype
cohortSQ1

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.300
  • TGF_BETA_SIGNALING+0.280
  • MITOTIC_SPINDLE+0.230
  • NOTCH_SIGNALING+0.230
  • APICAL_JUNCTION+0.220
  • P53_PATHWAY+0.210
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
  • KRAS_SIGNALING_UP+0.200
  • APICAL_SURFACE+0.190
  • INTERFERON_GAMMA_RESPONSE+0.190

Top 10 suppressed

  • OXIDATIVE_PHOSPHORYLATION-0.380
  • MTORC1_SIGNALING-0.370
  • PANCREAS_BETA_CELLS-0.370
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
  • HEME_METABOLISM-0.250
  • HEDGEHOG_SIGNALING-0.230
  • MYC_TARGETS_V1-0.230
  • UV_RESPONSE_UP-0.230
  • ADIPOGENESIS-0.210
  • UNFOLDED_PROTEIN_RESPONSE-0.170

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-BH-A0B5-01A-11R-A12P-07
breast-umap@18
—A0.743
2s_150203_3a
medullo-epn-umap@date-based
EPNSupratentorial EPN0.741
3TCGA-93-A4JN-01A-11R-A24X-07
lung-landscapes@6
—cohortA10.737
4TCGA-85-8287-01A-11R-2296-07
lung-landscapes@6
—cohortSQ10.698
557f2cc66-9163-4e07-93f8-d5a2158e7125
melanoma-umap@29
——0.678
6BSR_12_0175_A5_S64
breast-umap@18
—D0.647
7MNG1006
mng-umap@100
——0.644
8SRR6079981
head-neck@1
——0.642
9TCGA-44-7662-01A-11R-2066-07
lung-landscapes@6
—cohortA10.637
10BS_TQ5QHR17
brain-umap@2
Neurofibroma—0.635

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.300Inavolisib— uncovered
TGF_BETA_SIGNALING0.280Inavolisib— uncovered
MITOTIC_SPINDLE0.230Inavolisib— uncovered
NOTCH_SIGNALING0.230Inavolisib— uncovered
APICAL_JUNCTION0.220Inavolisib— uncovered
P53_PATHWAY0.210Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.200Inavolisib— uncovered
KRAS_SIGNALING_UP0.200Inavolisib— uncovered
APICAL_SURFACE0.190Temsirolimus— uncovered
INTERFERON_GAMMA_RESPONSE0.190Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.160Inavolisib— uncovered
UV_RESPONSE_DN0.140Inavolisib— uncovered
E2F_TARGETS0.130Inavolisib— uncovered
G2M_CHECKPOINT0.130Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.130Inavolisib— uncovered
DNA_REPAIR0.090Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.080Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.080Inavolisib— uncovered
ANGIOGENESIS0.070Remibrutinib— uncovered
ESTROGEN_RESPONSE_EARLY0.060Inavolisib— uncovered